Watch for Nonpsychotropics Causing Psychiatric Side Effects

Total Page:16

File Type:pdf, Size:1020Kb

Watch for Nonpsychotropics Causing Psychiatric Side Effects Watch for nonpsychotropics causing psychiatric side effects Look behind the scenes for drugs that play a supporting role in new mood symptoms r. J, age 52, has a history of opioid® dependence.Dowden Health Media Four weeks after starting interferon therapy for Mhepatitis C, he presents to the outpatient mental health clinic with depressedCopyright mood, irritability,For personal decreased use only energy, poor concentration, insomnia, anhedonia, and suicidal ideation. Because Mr. J has no history of depression, the psychia- trist diagnoses him with depressive disorder secondary to interferon. Interferon is stopped. Mr. J’s mood improves, HIATRY but he wants to restart interferon. c The psychiatrist starts Mr. J on sertraline, 50 mg/d, then gradually increases the dose to 150 mg/d as Mr. J’s mood symptoms return. Subsequently, the patient continues in- terferon with a combination of sertraline and supportive psychotherapy. BLAIR KELLY BLAIRFOR CURRENT KELLY PSY Recognizing a medication as the possible cause of your Kanwaldeep S. Sidhu, MD patient’s psychiatric symptoms can avoid inaccurate Third-year resident diagnosis and nonindicated psychiatric treatment. Dil- Richard Balon, MD Professor igently evaluating patients for drug-related psychiatric side effects is critical because complications usually are reversed when the offending drug is discontinued. Department of Psychiatry and Behavioral Neurosciences Wayne State University Unfortunately, a thin line separates available evidence Detroit, MI from anecdotal myths about psychiatric complications of nonpsychotropics. Almost two-thirds (65%) of drugs included in the Physicians’ Desk Reference list potential psychiatric side effects, according to a random sample review.1 In some patients, such as Mr. J, these effects can exacerbate mood symptoms and result in perceptual, cognitive, or Current Psychiatry behavioral disturbances. Vol. 7, No. 4 61 continued For mass reproduction, content licensing and permissions contact Dowden Health Media. Table New-onset psychiatric symptoms? Check patient’s drug list Symptom Documented as a possible cause Psychosis/ Anabolic androgenic steroids, antihistamines, clonidine, corticosteroids, agitation decongestants, didanosine, ethionamide, H2 blockers, isoniazid, nitrates, NSAIDs, Nonpsychotropic opioids, proton pump inhibitors, quinolones, salbutamol, skeletal muscle relaxants, medications sulfonamides/trimethoprim Anxiety Acyclovir, anabolic androgenic steroids, clonidine, corticosteroids, cyclosporine, decongestants, didanosine, serotonin 5-HT1 agonists such as sumatriptan, foscarnet, ganciclovir, nitrates, ondansetron, penicillins, skeletal muscle relaxants Depression Anabolic androgenic steroids, beta blockers, chloramphenicol, clonidine, corticosteroids, didanosine, digoxin, efavirenz, foscarnet, GnRH agonists, H2 blockers, interferons, isoniazid, isotretinoin, NSAIDs, quinolones, statins, tetracyclines Clinical Point Delirium ACE inhibitors, anabolic androgenic steroids, antibiotics (most), anticholinergics, beta blockers, centrally acting antihypertensives such as methyldopa and Beta blockers such reserpine, cimetidine, clonidine, corticosteroids, didanosine, digoxin, H2 blockers, as metoprolol and lidocaine, naltrexone, nitrates, NSAIDs, opioids propranolol can Insomnia Aminophylline, anabolic androgenic steroids, clonidine, corticosteroids, decongestants, didanosine, opioid antagonists, proton pump inhibitors, quinolone cause delirium and antibiotics, salbutamol, skeletal muscle relaxants, tetracyclines psychosis NSAIDs: nonsteroidal anti-inflammatory drugs; ACE: angiotensin-converting enzyme; GnRH: gonadotropin-releasing hormone Source: Prepared for CURRENT PSYcHIATRY by Drs. Sidhu and Balon from references cited in this article A wide range of drugs can cause psycho- Metoprolol and propranolol can induce sis, agitation, anxiety, depression, delirium, delirium and psychosis.4,5 Psychiatric side or insomnia (Table). On the other hand, cer- effects with metoprolol are frequent,4 and tain psychiatric side effects of nonpsycho- propranolol has been associated with: tropics can be beneficial Box( 1). • sedation (affecting >10% of patients) Improve your assessments by examin- • nightmares ing the evidence linking psychiatric side • visual impairment effects to commonly prescribed and over- • hallucinations the-counter (OTC) compounds, including: • delirium • cardiovascular medications • depression.5 • steroids (prescription and illegal) In 1967, it was reported that up to 50% • hormones of patients taking propranolol may experi- • interferons ence dysphoria and at times severe depres- • antimicrobials. sion.6 These effects may occur acutely or develop gradually. 5 The relationship between depressive Cardiovascular medications symptoms and beta blockers has been in- Beta blockers have CNS effects—some of creasingly questioned, however. One study which cause psychiatric syndromes—that did not find a higher prevalence of depres- might depend on an ancillary property sion in patients receiving beta blockers vs such as lipophilicity.2 Unlike hydrophilic those receiving other medications, although agents such as atenolol that are excreted this trial had major methodologic limita- unchanged by the kidneys, lipophilic tions.7 One large study found no significant drugs such as metoprolol and propranolol association between beta-blocker use and are metabolized by the liver and are be- major depression, regardless of patient age, lieved to enter the brain. Metoprolol has a gender, or race.8 brain/plasma concentration ratio about 20 These studies stress the importance of Current Psychiatry 62 April 2008 times higher than that of atenolol.3 carefully assessing the individual patient before assigning neurotoxicity to beta block- Box 1 ers, as these drugs have considerable ben- efits for cardiovascular disease.9 Not all psychiatric side effects are harmful Angiotensin-converting enzyme (ACE) inhibitors also affect the CNS. About 4% n some instances, mood-elevating side effects of nonpsychotropic medications to 8% of patients taking an ACE inhibitor I might be beneficial. This might be the experience altered mental status—typically case if your patient experiences a sudden, increased arousal and psychomotor activ- otherwise unexplainable improvement. ity—although <2% discontinue the medica- tion because of neuropsychiatric side effects. CASE Helped by corticosteroids These include: Ms. Q, age 44, has a history of asthma and • anxiety major depressive disorder and is being • mania treated by a resident psychiatrist with • insomnia a combination of paroxetine, 60 mg/d, • fatigue mirtazapine, 15 mg at night, and cognitive- • paresthesias behavioral therapy. Her treatment has been Clinical Point • hallucinations.5 challenging, and the psychiatrist has tried Mood changes Sedation occurs in about 5% of patients multiple medications and psychotherapy modalities. are the most taking ACE inhibitors. Depression and sui- At a recent psychotherapy session, Ms. cide ideation as a result of ACE inhibition common psychiatric Q says she has been feeling much better, have been reported;13 however, ACE inhibi- symptoms caused by with improved mood and greater energy. tors have also been known to improve de- Upon further questioning, she reports corticosteroids pression. Episodes of frank delirium have having an asthma exacerbation a week 5 been reported. before that resulted in hospitalization. During her stay, Ms. Q was started on Clonidine is a centrally acting alpha- a tapering dose of prednisone, which agonist. The alpha-adrenergic system regu- elevated her mood. Depressive symptoms lates arousal and has an important role in returned when the effects of the major depression, anxiety states, and other prednisone wore off. arousal disorders. Prednisone is not indicated for depression and has harmful effects when More than one-third (35%) of patients tak- used long term. The psychiatrist adds ing clonidine experience sedation or lethar- bupropion, 300 mg/d, to Ms. Q’s regimen, gy; less commonly, the drug causes anxiety and her symptoms improve. (3%), agitation (3%), depression (1%), and insomnia (1%).5 Acute confusion, delirium, hypomania, and psychosis related to cloni- suicide, but the evidence is inconclusive. dine use have long been recognized, occur- Some studies have supported this link,10,11 ring in <1% of patients—primarily those whereas others have strongly refuted it12,13 with preexisting cerebrovascular disease.5 or had mixed results.14 A recent review15 rec- ommends being vigilant for psychiatric side Other cardiovascular drugs. Side effects of effects in patients taking these drugs. nitrates/nitrites include delirium, psychosis (including delusions), anxiety, restlessness, agitation, and hypomania.5 Digoxin can Steroids: prescription and illegal cause cardiac glycoside-induced encepha- Corticosteroids are prescribed for a variety lopathy, which may present as sedation, of immune system-related diseases, includ- apathy, depression, and psychosis. Patients ing asthma, allergic rhinitis, rheumatoid may develop delirium, even when digoxin/ arthritis, inflammatory bowel disease, and digitoxin serum levels are within a thera- dermatologic disorders. Mood changes are peutic range. the most common psychiatric symptoms Cholesterol-lowering statins might be caused by corticosteroid use; delirium is less Current Psychiatry linked to an increased risk of depression and common. Psychiatric side effects include: Vol. 7, No. 4 63 • lethargy cases or situations in which
Recommended publications
  • And Inter-Personal Emotion Regulation
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by YorkSpace EXAMINING INTRA- AND INTER-PERSONAL EMOTION REGULATION, PSYCHOPATHOLOGY, WELL-BEING, AND RELATIONSHIP QUALITY IN EMERGING ADULTHOOD SAMANTHA CHAN A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF ARTS GRADUATE PROGRAM IN CLINICAL DEVELOPMENTAL PSYCHOLOGY YORK UNIVERSITY TORONTO, ONTARIO AUGUST 2019 Ó Samantha Chan, 2019 ii Abstract Identifying components of emotion regulation (ER) that contribute to emerging adults’ (18-29 years) psychosocial outcomes is crucial to promoting their development. This study aimed to identify emerging adults’ intra- and inter-personal ER strategy use and explore the associations between their ER strategy use and difficulties and psychosocial outcomes, including internalizing symptoms (depressive and anxiety symptoms and perceived stress), well-being (subjective happiness and flourishing), and relationship quality. Results showed that emerging adults utilized a range of intra- (e.g., acceptance,) and inter-personal (e.g., enhancing positive affect) ER strategies. The structural equation modelling results indicated that emotion dysregulation was the strongest predictor of emerging adults’ psychosocial outcomes. Some ER strategies (e.g., positive reappraisal, enhancing positive affect) were more strongly associated with emerging adults’ psychosocial outcomes than other strategies. The findings highlight the links between intra- and inter-personal ER and emerging adults’ psychosocial outcomes and can inform mental health intervention programs for emerging adults. iii Acknowledgements First and foremost, I would like to thank my supervisor, Dr. Jennine Rawana for all of her invaluable advice and support with this research.
    [Show full text]
  • Table 2. 2012 AGS Beers Criteria for Potentially
    Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May
    [Show full text]
  • Switching from Clonidine Immediate-Release to Guanfacine Extended-Release
    / DE L’ACADÉMIE CANADIENNE DE PSYCHIATRIE DE L’ENFANT ET DE L’ADOLESCENT PSYCHOPHARMACOLOGY Switching from Clonidine Immediate-Release to Guanfacine Extended-Release Dean Elbe PharmD, BCPP1,2,3 s a clinical pharmacy specialist in child and adolescent (Canada) Ltd, 2012b). Clonidine has been used off-label Amental health, I am frequently asked how to switch in children for many years for treatment of insomnia, patients from clonidine immediate-release (IR) to guanfa- ADHD, and disruptive behaviour disorders (Hunt, Capper cine extended-release (XR). This therapeutic switch may be & O’Connell, 1990; Rubinstein; Jaselskis, Cook, Fletcher required when poor adherence to a clonidine IR regimen & Leventhal, 1992; Silver & Licamele, 1994; Palumbo et (typically requiring 3–4 doses daily) is identified, when al., 2008; Efron, Lycett & Sciberras, 2014). A clonidine XR clonidine dose-optimization is limited by sedation, brady- formulation is not available in Canada, but is available in cardia or hypotension, or when coverage situations change. the United States for treatment of ADHD (Concordia Phar- The latter may occur if, for example, new eligibility for a maceuticals, Inc. 2015). government program or a third party-payer occurs. Weight-based dosing guidelines exist for clonidine IR Guanfacine XR, a selective alpha2A agonist, was first mar- (0.003–0.008 mg/kg/day) and guanfacine XR (0.05–0.08 keted in Canada in late 2013 for the treatment of attention mg/kg/day) (Shire Pharma Canada ULC, 2019; Elbe et deficit hyperactivity disorder (ADHD) in children and ado- al., 2018). Based on these guidelines and other literature, lescents (Shire Pharma Canada ULC, 2019).
    [Show full text]
  • Is Your Depressed Patient Bipolar?
    J Am Board Fam Pract: first published as 10.3122/jabfm.18.4.271 on 29 June 2005. Downloaded from EVIDENCE-BASED CLINICAL MEDICINE Is Your Depressed Patient Bipolar? Neil S. Kaye, MD, DFAPA Accurate diagnosis of mood disorders is critical for treatment to be effective. Distinguishing between major depression and bipolar disorders, especially the depressed phase of a bipolar disorder, is essen- tial, because they differ substantially in their genetics, clinical course, outcomes, prognosis, and treat- ment. In current practice, bipolar disorders, especially bipolar II disorder, are underdiagnosed. Misdi- agnosing bipolar disorders deprives patients of timely and potentially lifesaving treatment, particularly considering the development of newer and possibly more effective medications for both depressive fea- tures and the maintenance treatment (prevention of recurrence/relapse). This article focuses specifi- cally on how to recognize the identifying features suggestive of a bipolar disorder in patients who present with depressive symptoms or who have previously been diagnosed with major depression or dysthymia. This task is not especially time-consuming, and the interested primary care or family physi- cian can easily perform this assessment. Tools to assist the physician in daily practice with the evalua- tion and recognition of bipolar disorders and bipolar depression are presented and discussed. (J Am Board Fam Pract 2005;18:271–81.) Studies have demonstrated that a large proportion orders than in major depression, and the psychiat- of patients in primary care settings have both med- ric treatments of the 2 disorders are distinctly dif- ical and psychiatric diagnoses and require dual ferent.3–5 Whereas antidepressants are the treatment.1 It is thus the responsibility of the pri- treatment of choice for major depression, current mary care physician, in many instances, to correctly guidelines recommend that antidepressants not be diagnose mental illnesses and to treat or make ap- used in the absence of mood stabilizers in patients propriate referrals.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Conceptual Model for Using Imidazoline Derivative Solutions in Pulpal Management
    Journal of Clinical Medicine Review Conceptual Model for Using Imidazoline Derivative Solutions in Pulpal Management Robert S. Jones Division of Pediatric Dentistry, Department of Developmental & Surgical Sciences, School of Dentistry, University of Minnesota, Minneapolis, MN 55455, USA; [email protected] Abstract: Alpha-adrenergic agonists, such as the Imidazoline derivatives (ImDs) of oxymetazoline and xylometazoline, are highly effective hemostatic agents. ImDs have not been widely used in dentistry but their use in medicine, specifically in ophthalmology and otolaryngology, warrants consideration for pulpal hemostasis. This review presents dental healthcare professionals with an overview of ImDs in medicine. ImD solutions have the potential to be more effective and biocompatible than existing topical hemostatic compounds in pulpal management. Through a comprehensive analysis of the pharmacology of ImDs and the microphysiology of hemostasis regulation in oral tissues, a conceptual model of pulpal management by ImD solutions is presented. Keywords: hemostasis; alpha-adrenergic agonists; imidazoline; oxymetazoline; nasal; dental pulp; mucosa; apexogenesis; pulpotomy; direct pulp cap; dentistry 1. Overview Citation: Jones, R.S. Conceptual The purpose of this review is to formulate a conceptual model on the potential man- Model for Using Imidazoline agement of pulpal tissue by imidazoline derivatives (ImDs) based on a review of the Derivative Solutions in Pulpal literature that examines the hemostatic properties and mechanistic actions of these com- Management. J. Clin. Med. 2021, 10, 1212. https://doi.org/10.3390/ pounds in other human tissues. Commercial ImDs are formulated in solution with an- jcm10061212 timicrobial preservatives in order to act as ‘parenteral topical agents’ and used to manage ophthalmic inflammation, nasal congestion, and to control bleeding during otolaryngology Academic Editor: Rosalia surgery [1,2].
    [Show full text]
  • Conflict, Arousal, and Logical Gut Feelings
    CONFLICT, AROUSAL, AND LOGICAL GUT FEELINGS Wim De Neys1, 2, 3 1 ‐ CNRS, Unité 3521 LaPsyDÉ, France 2 ‐ Université Paris Descartes, Sorbonne Paris Cité, Unité 3521 LaPsyDÉ, France 3 ‐ Université de Caen Basse‐Normandie, Unité 3521 LaPsyDÉ, France Mailing address: Wim De Neys LaPsyDÉ (Unité CNRS 3521, Université Paris Descartes) Sorbonne - Labo A. Binet 46, rue Saint Jacques 75005 Paris France [email protected] ABSTRACT Although human reasoning is often biased by intuitive heuristics, recent studies on conflict detection during thinking suggest that adult reasoners detect the biased nature of their judgments. Despite their illogical response, adults seem to demonstrate a remarkable sensitivity to possible conflict between their heuristic judgment and logical or probabilistic norms. In this chapter I review the core findings and try to clarify why it makes sense to conceive this logical sensitivity as an intuitive gut feeling. CONFLICT, AROUSAL, AND LOGICAL GUT FEELINGS Imagine you’re on a game show. The host shows you two metal boxes that are both filled with $100 and $1 dollar bills. You get to draw one note out of one of the boxes. Whatever note you draw is yours to keep. The host tells you that box A contains a total of 10 bills, one of which is a $100 note. He also informs you that Box B contains 1000 bills and 99 of these are $100 notes. So box A has got one $100 bill in it while there are 99 of them hiding in box B. Which one of the boxes should you draw from to maximize your chances of winning $100? When presented with this problem a lot of people seem to have a strong intuitive preference for Box B.
    [Show full text]
  • Perceived Social Rank, Social Expectation, Shame and General Emotionality Within Psychopathy
    Perceived social rank, social expectation, shame and general emotionality within psychopathy Sarah Keen D. Clin.Psy. Thesis (Volume 1), 2008 University College London UMI Number: U591545 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. Dissertation Publishing UMI U591545 Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author. Microform Edition © ProQuest LLC. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Overview Within the psychological literature, the self-conscious emotion of shame is proving to be an area of growing interest. This thesis addresses the application of this emotion, as well as self and social evaluative processes, to our understanding of offenders, specifically those high in psychopathic traits. Part 1 reviews the literature concerning emotionality within psychopathy, in order to assess the capabilities, as well as the deficits that people with psychopathic traits demonstrate. Emotions classified as ‘moral’ or ‘self-conscious’, namely empathy, sympathy, guilt, remorse, shame, embarrassment and pride, are investigated. From the review it is clear that psychopaths are not the truly unemotional individuals that they are commonly portrayed as being, but instead experience many emotions to varying degrees. This paper concludes by highlighting possible areas for further exploration and research.
    [Show full text]
  • Social Emotional Learning Through Depression Education in a High School Setting
    Illinois State University ISU ReD: Research and eData Theses and Dissertations 3-10-2019 Social Emotional Learning Through Depression Education In A High School Setting Antonette Minniti Illinois State University, [email protected] Follow this and additional works at: https://ir.library.illinoisstate.edu/etd Part of the Educational Psychology Commons, Elementary and Middle and Secondary Education Administration Commons, Public Health Education and Promotion Commons, School Psychology Commons, Secondary Education and Teaching Commons, and the Student Counseling and Personnel Services Commons Recommended Citation Minniti, Antonette, "Social Emotional Learning Through Depression Education In A High School Setting" (2019). Theses and Dissertations. 1043. https://ir.library.illinoisstate.edu/etd/1043 This Dissertation is brought to you for free and open access by ISU ReD: Research and eData. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of ISU ReD: Research and eData. For more information, please contact [email protected]. SOCIAL EMOTIONAL LEARNING THROUGH DEPRESSION EDUCATION IN A HIGH SCHOOL SETTING Antonette Minniti 125 Pages Education on depression is an important part of social emotional learning. Lacking emotion regulation skills tend to lead to larger problems, such as academic struggles, disconnect from peers, strife at home and trouble in interpersonal relationships. Research in depression education or educational programs connected to mental health literacy are minimal, especially at the high school level. The purpose of this research focused on examining the impact of one depression education program, John Hopkins Hospital’s Adolescent Depression Awareness Program (ADAP). The ADAP is a three-day program that informs students about the facts of depression, how it is treated, and what to do if the individual students or someone they know needs help with depression.
    [Show full text]
  • Panic Disorder Issue Brief
    Panic Disorder OCTOBER | 2018 Introduction Briefings such as this one are prepared in response to petitions to add new conditions to the list of qualifying conditions for the Minnesota medical cannabis program. The intention of these briefings is to present to the Commissioner of Health, to members of the Medical Cannabis Review Panel, and to interested members of the public scientific studies of cannabis products as therapy for the petitioned condition. Brief information on the condition and its current treatment is provided to help give context to the studies. The primary focus is on clinical trials and observational studies, but for many conditions there are few of these. A selection of articles on pre-clinical studies (typically laboratory and animal model studies) will be included, especially if there are few clinical trials or observational studies. Though interpretation of surveys is usually difficult because it is unclear whether responders represent the population of interest and because of unknown validity of responses, when published in peer-reviewed journals surveys will be included for completeness. When found, published recommendations or opinions of national organizations medical organizations will be included. Searches for published clinical trials and observational studies are performed using the National Library of Medicine’s MEDLINE database using key words appropriate for the petitioned condition. Articles that appeared to be results of clinical trials, observational studies, or review articles of such studies, were accessed for examination. References in the articles were studied to identify additional articles that were not found on the initial search. This continued in an iterative fashion until no additional relevant articles were found.
    [Show full text]
  • The Effect of Opioids on Emotional Reactivity
    The Effect of Opioids on Emotional Reactivity Steven M. Savvas, BHSc (Hons) Discipline of Pharmacology, School of Medical Sciences, Faculty of Health Sciences University of Adelaide August, 2013 A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy i Steven M. Savvas, PhD Thesis, 2013 TABLE OF CONTENTS Abstract .................................................................................................................................... xi Declaration ............................................................................................................................ xiii Acknowledgements ............................................................................................................... xiv CHAPTER 1 - INTRODUCTION ...................................................................................... 1 1.1 OPIOIDS AND OPIOID MAINTENANCE TREATMENT ...................................... 1 1.1.1 A BRIEF HISTORY OF OPIOIDS .......................................................................... 1 1.1.2 OPIOID RECEPTORS ............................................................................................ 1 1.1.3 ADAPTATION TO OPIOIDS.................................................................................. 3 1.1.3.1 Tolerance ........................................................................................................ 4 1.1.3.2 Withdrawal ...................................................................................................... 4 1.1.3.3 Dependence
    [Show full text]
  • Cotard's Syndrome: Two Case Reports and a Brief Review of Literature
    Published online: 2019-09-26 Case Report Cotard’s syndrome: Two case reports and a brief review of literature Sandeep Grover, Jitender Aneja, Sonali Mahajan, Sannidhya Varma Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India ABSTRACT Cotard’s syndrome is a rare neuropsychiatric condition in which the patient denies existence of one’s own body to the extent of delusions of immortality. One of the consequences of Cotard’s syndrome is self‑starvation because of negation of existence of self. Although Cotard’s syndrome has been reported to be associated with various organic conditions and other forms of psychopathology, it is less often reported to be seen in patients with catatonia. In this report we present two cases of Cotard’s syndrome, both of whom had associated self‑starvation and nutritional deficiencies and one of whom had associated catatonia. Key words: Catatonia, Cotard’s syndrome, depression Introduction Case Report Cotard’s syndrome is a rare neuropsychiatric condition Case 1 characterized by anxious melancholia, delusions Mr. B, 65‑year‑old retired teacher who was pre‑morbidly of non‑existence concerning one’s own body to the well adjusted with no family history of mental illness, extent of delusions of immortality.[1] It has been most with personal history of smoking cigarettes in dependent commonly seen in patients with severe depression. pattern for last 30 years presented with an insidious However, now it is thought to be less common possibly onset mental illness of one and half years duration due to early institution of treatment in patients precipitated by psychosocial stressors.
    [Show full text]